TRISCEND II Pivotal Trial : How will TTVR impact the treatment of tricuspid regurgitation?

Supported by Edwards Lifesciences

Summary

In this roundtable discussion, Marianna Adamo, Philipp Lurz, and Sam Dawkins explore the one-year outcomes of the TRISCEND II Pivotal Trial, highlighting its potential to redefine the management of severe tricuspid regurgitation. They delve into the trial’s impact on patients’ quality of life, examine its limitations, and discuss the clinical significance of these groundbreaking results.

This interview was filmed at PCR London Valves 2024: see more videos here.